Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mega lifesciences sdn. bhd. - cetirizine dihydochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - ascorbic acid,colecalciferol,cyanocobalamin,dl-alpha-tocopheryl acetate,folic acid,lysine hydrochloride,nicotinamide,pyridoxine hydrochloride,retinol acetate,riboflavine,thiamine hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - zinc sulfate monohydrate, quantity: 20.6 mg (equivalent: zinc, qty 7.5 mg); cupric sulfate pentahydrate, quantity: 3.928 mg (equivalent: copper, qty 1 mg); manganese sulfate monohydrate, quantity: 5.539 mg (equivalent: manganese, qty 1.8 mg); dried magnesium sulfate, quantity: 317.46 mg (equivalent: magnesium, qty 40 mg); borax, quantity: 2.205 mg (equivalent: boron, qty 0.25 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600 mg); colecalciferol, quantity: 0.005 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; magnesium stearate; maltodextrin; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified talc; allura red ac; polyvinyl alcohol; macrogol 3350; lecithin; maize starch; acacia; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides; polysorbate 80; macrogol 4000 - maintain/support bone health ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - riboflavine, quantity: 0.25 mg; nicotinamide, quantity: 2.5 mg; colecalciferol, quantity: 0.0025 mg; ascorbic acid, quantity: 50 mg; lysine hydrochloride, quantity: 50 mg; thiamine hydrochloride, quantity: 0.25 mg; pyridoxine hydrochloride, quantity: 0.25 mg (equivalent: pyridoxine, qty 205 microgram); cyanocobalamin, quantity: 2 microgram; folic acid, quantity: 250 microgram; dl-alpha-tocopheryl acetate, quantity: 10 mg; retinol acetate, quantity: 0.5307 mg - tablet, chewable - excipient ingredients: maltodextrin; glucose monohydrate; magnesium stearate; sucralose; hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; maize starch; acacia; dl-alpha-tocopherol; spray-dried glucose syrup; silicon dioxide; flavour; sucrose; medium chain triglycerides; colour - maintain/support healthy appetite ; enhance/improve/promote/increase nutrient uptake ; enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body

Κένυα - Αγγλικά - Pharmacy and Poisons Board

mega lifesciences public company ltd 384 moo 4, soi 6, bangpoo industrial estate, - simethicone , alverine citrate - capsule, soft - simethicone 300mg , alverine citrate 60mg - other drugs for functional gastrointestinal

Κένυα - Αγγλικά - Pharmacy and Poisons Board

mega lifesciences public company ltd 384 moo 4, bangpoo industrial estate, pattana 3 - ibuprofen usp - capsule, soft - ibuprofen usp 200mg - ibuprofen

Κένυα - Αγγλικά - Pharmacy and Poisons Board

mega lifesciences public company ltd 384 , soi 6, bangpoo industrial estate , pattana - calcium polystyrene sulfonate - powder for oral/rectal suspension - each sachet contains calcium polystyrene… - polystyrene sulfonate

Κένυα - Αγγλικά - Pharmacy and Poisons Board

mega lifesciences public company ltd 384 moo 4, soi 6, bangpoo industrial estate, - finasteride - coated tablet - finasteride 5mg - testosterone-5-alpha reductase inhibitors used

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

par pharmaceutical inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting  therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug ther

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

golden state medical supply, inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -   usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -